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Abstract The hepatocyte growth factor/c-MET pathway has
been implicated in the pathobiology of multiple myeloma, and
c-MET inhibitors induce myeloma cell apoptosis, suggesting
that they could be useful clinically. We conducted a phase II
study with the c-MET inhibitor tivantinib in patients with
relapsed, or relapsed and refractory myeloma whose disease
had progressed after one to four prior therapies. Tivantinib,
360 mg orally per dose, was administered twice daily contin-
uously over a 4-week treatment cycle without a cap on the
number of allowed cycles, barring undue toxicities or disease
progression. Primary objectives were to determine the overall
response rate and the toxicities of tivantinib in this patient
population. Sixteen patients were enrolled in a two-stage de-
sign. Notable grade 3 and 4 hematological adverse events
were limited to neutropenia in five and four patients, respec-
tively. Nonhematological adverse events of grade 3 or higher
included hypertension (in four patients); syncope, infection,
and pain (two each); and fatigue, cough, and pulmonary em-
bolism (one each). Four of 11 evaluable patients (36%) had
stable disease as their best response, while the remainder
showed disease progression. Overall, tivantinib as a single
agent did not show promise for unselected relapsed/
refractory myeloma patients. However, the ability to achieve
stable disease does suggest that combination regimens incor-
porating targeted inhibitors in patients with c-MET pathway
activation could be of interest.
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Multiple myeloma is the second most commonly diagnosed
hematologic malignancy, and the total number of new cases
may show a 60% increase between 2010 and 2030 [1], indi-
cating that it is an increasing health care burden. Introduction
over the past decade of proteasome inhibitors, immunomodu-
latory agents, and their combinations has improved the out-
come of patients with relapsed and relapsed/refractory myelo-
ma [2]. Nevertheless, patients still experience multiple re-
lapses and decreasing remission durations with each addition-
al line of therapy [2], and those with refractory disease in
particular may not respond favorably to standard agents.
Their use is limited by treatment-emergent toxicity, or by in-
trinsic or acquired resistance, underscoring the continued need
for novel treatments.
Activation of the c-MET receptor tyrosine kinase induced
by its ligand, hepatocyte growth factor (HGF), plays a role in
myeloma pathobiology. Malignant plasma cells secrete HGF
activator (HGFA), which converts HGF to its active form, and
high HGF levels correlate with a poor prognosis [3, 4].
Syndecan 1 (CD138) on myeloma cells binds HGF and pro-
motes c-MET signaling [5], while both potentiate interleukin-
6-induced growth and migration, correlating with shorter sur-
vival [6]. Preclinical studies showed that suppression of c-
MET signaling with small molecule inhibitors, including
tivantinib, inhibited proliferation and induced apoptosis
[7–10]. Preclinically, tivantinib-mediated cytotoxicity was ob-
served at concentrations <5 μM, a level achievable in the
clinic that showed activity in solid tumors with a dose of
360 mg twice daily [11]. Phase II single-agent tivantinib stud-
ies demonstrated efficacy in solid tumors [12], and the com-
bination of tivantinib and erlotinib was tested in a phase III
trial in nonsmall cell lung carcinoma and showed an improve-
ment for the two-drug regimen in progression-free, though not
overall survival [13]. Finally, biomarker studies demonstrated
the efficacy of tivantinib in inhibiting MET receptor kinase, as
well as inducing apoptosis of target tumor cells [11]. Together,
these findings supported the hypothesis that suppressing
HGF/c-MET signaling could be a rational strategy against
relapsed/refractory myeloma, and we therefore performed a
phase II clinical trial testing this possibility.
Patients and methods
Patient selection
Patients with histologically confirmed symptomatic myeloma
by the International Myeloma Working Group (IMWG)
criteria with 1–4 prior lines of therapy were eligible. They
had to have measurable disease that had relapsed after, or
was refractory to the prior regimen. Additional key inclusion
criteria included: (1) Eastern Cooperative Oncology Group
(ECOG) performance status of 0–2, (2) adequate bone mar-
row reserves [absolute neutrophil count (ANC) ≥1000 cells/
mm3, hemoglobin ≥8 g/dL; platelets ≥100,000 cells/mm3],
and (3) adequate hepatic [total bilirubin ≤1.5× normal, aspar-
tate and alanine aminotransferase ≤2.5× normal], renal [nor-
mal serum creatinine, or creatinine clearance ≥30 mL/min],
and cardiac function [absence of New York Heart
Association class II-IV congestive heart failure, uncontrolled
angina, hypertension, myocardial infarction within 6 months,
or grade 3–4 cardiac arrhythmia by NCI Common
Terminology Criteria for Adverse Events (CTCAE), version
4.0]. Key exclusion criteria included: (1) central nervous sys-
tem involvement, (2) previous treatment with another agent
targeting HGF/c-MET, and (3) nonsecretory myeloma, active
plasma cell leukemia, or POEMS syndrome (polyneuropathy,
organomegaly, endocrinopathy, monoclonal gammopathy,
and skin changes). The MD Anderson Institutional Review
Board approved the trial. Informed consent was obtained from
all patients for being included in the study. All procedures
followed were in accordance with the ethical standards of
the responsible committee on human experimentation (insti-
tutional and national) and with the Helsinki Declaration of
1975, as revised in 2008. This study was registered with
Clinicaltrials.gov (NCT01447914).
Study design
This open-label, phase II study used a Simon’s Minimax 2-
stage design. A response rate of ≤10% was considered as
clinically insignificant, while 30% was considered significant.
When the probabilities of accepting a Bbad^ drug and of
rejecting a Bgood^ drug are both 0.1, the Simon Minimax 2-
stage design required 16 patients in the first stage. Another
nine would have been enrolled had there been evidence of ≥1
documented partial remission (PR) or better.
The primary objectives were to determine the overall re-
sponse rate (ORR) to tivantinib and to define its toxicities.
Secondary objectives were (1) to obtain preliminary evidence
of response durability, (2) to correlate HGF/c-MET pathway
activation in primary cells at baseline with efficacy, and (3) to
correlate serum and marrow HGF, HGFA, and soluble c-MET
(sc-MET) levels with HGF/c-MET pathway activation in pri-
mary cells at baseline and after treatment.
An exploratory objectivewas to evaluate the symptomburden
of patients using the MD Anderson Symptom Inventory
(MDASI) and its myeloma module (MDASI-MM). This brief,
validated [14], patient-reported outcome tool measured 13
cancer-related symptoms and their impact on daily living. The
symptoms assessed included pain, fatigue, nausea, disturbed
sleep, distress, shortness of breath, difficulty remembering, lack
of appetite, drowsiness, dry mouth, sadness, vomiting, numb-
ness, constipation, muscle weakness, diarrhea, mouth or throat
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sores, rash, and trouble concentrating. Six additional items
assessed symptom-related interference in general activity, mood,
work, relation with others, enjoyment of life, and walking.
MDASI scores were scored numerically from 0 to 10 (symptom
absence to as bad as imaginable). Another exploratory objective
evaluated patient-reported outcomes using the European
Organization for Research on the Treatment of Cancer
(EORTC) Quality of Life Questionnaire (QLQ) Core 30
(QLQ-C30) and the myeloma-specific module QLQ-MY20.
Questions relating to overall health and quality of life in the
QLQ-C30 were rated from 1 to 7 (very poor to excellent), while
the remaining questions were graded qualitatively, in ascending
severity, with not at all, a little, quite a bit, or very much.
Drug dosing and assessments
Tivantinib, provided through the National Cancer Institute
Cancer Therapy Evaluation Program (CTEP), was adminis-
tered at 360 mg p.o. (three tablets of 120 mg) with meals twice
daily of every 4-week cycle, and at this dose level, steady-state
plasma tivantinib levels in a phase I trial were 7 μM [11].
Treatment was to be continued unless patients experienced
undue toxicities, disease progression, or withdrew consent.
In the event of treatment-emergent grade 2 rash or hand-foot
syndrome, grade 3 nonhematologic toxicities, or grade 4 he-
matologic adverse events (AEs), the drug was held until these
returned to grade 0–1 or the pretreatment baseline. At that
point, tivantinib was restarted at a reduced dose (level-1 dose,
240 mg twice daily; level-2 dose, 120 mg twice daily).
Response and toxicity assessment
An evaluation of disease response by IMWG criteria to deter-
mine eligibility to continue therapy was to be performed after
the first 2 cycles, and on day 1 of every cycle afterward.
Toxicity was monitored throughout treatment, with a special
focus on AEs during cycle 1. The toxicity endpoint was de-
fined as any treatment-related unmanageable toxicity, includ-
ing grade 3 nonhematologic or grade 4 hematologic effects
that required delay or treatment termination during cycle 1.
Rates of these toxicities ≥25% were considered unacceptable.
Sample collection
Pretreatment bone marrow samples were sorted into CD138+
and CD138− fractions at the MD Anderson Myeloma Tissue
Core Facility as described previously [15], and extracted and
labeled for gene expression profiling (GEP) [16]. Plasma sam-
ples were collected on day 1 of each cycle, and isolated and
stored until further analysis. HGF was determined using the
HGF enzyme-linked immunosorbent assay (ELISA)
(Invitrogen, Camarillo, CA) and analyzed using a Bio-Tek
PowerWave XS spectrophotometer (Winooski, VT).
Results
Patient characteristics
Sixteen patients enrolled between January, 2012, and April,
2013, and received a median of 3 cycles of therapy, with one
patient continuing until February, 2014. All patients were
evaluable for toxicity, while 11 were formally evaluable for
response after completing 2 cycles. The median patient age
was 66 years, and they had received a median of 1 prior line of
therapy (range 1–3). Additional demographic data are sum-
marized in Table 1.
Adverse events and treatment efficacy
There were no unexpected toxicities given the known AE
profile of tivantinib and no deaths. The most common AEs
in ≥25% of patients, and felt to be at least possibly drug-relat-
ed, included fatigue or decreased neutrophils (94% each), pain
(81%), myalgias (56%), diarrhea (38%), memory impairment,
respiratory disorders, and rash (31% each), hypertension
(25%), and these were predominantly grades 1–2 (Table 2).
Grade 3 or 4 AEs included neutropenia (31 and 25%, respec-
tively), syncope, infection, pain (13% of each, all grade 3),
and anal fissure, cough, fatigue, hypertension, and pulmonary
embolism (6% each, all grade 3).
Stable disease (SD) was observed as the best response in 4/
11 (36%) evaluable patients, or 4/16 (25%) patients who were
enrolled and received at least one dose of drug. This was
maintained for up to 15 cycles in patient 12, who withdrew
consent because other therapies were available, while the re-
maining 7/11 (63%) patients showed progression (PD).
Among the five inevaluable patients, treatment was stopped
prior to completing 2 cycles because of toxicity in two patients
(syncope/bradycardia and neutropenic fever), withdrawal of
consent in one, and PD in two patients (both showing a
progressing Bence-Jones paraprotein). While the protocol
did allow replacement of patients who were inevaluable for
response, after consultation with CTEP, and given the lack of
activity, a decision was made to halt enrollment.
Prior therapies received by the patients who experienced
SD included thalidomide and dexamethasone (Td) leading to
autologous stem cell transplantation (ASCT), and then
bortezomib and dexamethasone (Vd) at first relapse in patient
2; Vd, followed by bortezomib and pegylated liposomal doxo-
rubicin after first progression in patient 4; Td and ASCT in
patient 5; and Vd, followed after progression by lenalidomide,
bortezomib, and dexamethasone and then ASCT in patient 12.
The monoclonal protein (M-protein) evolution prior to, and
after, initiation of tivantinib therapy in SD patients who re-
ceived more than 2 cycles of therapy is depicted in Fig. 1. All
three patients had rising M-proteins at enrollment (patient 12
also had progressing Bence-Jones paraprotein, while patient 5
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had progressing serum free light chains and worsening throm-
bocytopenia) and met criteria for SD, though further exposure
to tivantinib yielded evidence of some benefit only in patient
12. In patients with SD, the median durability of response was
7 cycles (range 2–15) or 6.5 months (range 2–15). Two SD
patients ultimately withdrew consent (patients 2 and 5), while
patient 4 developed declining performance status that led to
discontinuation of treatment.
Symptom burden and quality of life
A total of 95 MDASI and 93 EORTC measurements were
collected, 63% of which were within 3 cycles of therapy. The
top five most severe MDASI symptoms were fatigue, pain,
numbness, limited activity, and muscle weakness (Table 3).
During the first cycle, five patients were asymptomatic (scoring
0–3), and four of these completed at least 3 cycles of therapy
and remained asymptomatic. Two patients reported >10 symp-
toms as moderate/severe (scoring 4–10) that significantly inter-
fered with their activity and enjoyment of life; most of those
symptoms did not improve over time.Most commonly reported
EORTC symptoms during cycle 1 related to tiredness, feeling
less attractive, thinking about illness, weakness, and pain inter-
ference with daily activities, while the overall top five EORTC
concerns were problems with strenuous activities, tiredness,
pain/aches, weakness, and problem with long walks (Table 4).
The QLQ-C30 questions on overall health and quality of life
were scored high consistently during the treatment despite cer-
tain patients experiencing PD. Interestingly, both parameters
decreased in two patients with SD.
Plasma HGF levels
A total of 79 plasma samples were collected, and two samples
were collected from healthy donors. The median plasma HGF
level in myeloma patients was 450 pg/mL (range 150–5991)
(Fig. 2, A-C) at baseline and was <600 pg/mL in the majority
(10/16), while the HGF levels in the two healthy donors were
60 and 1400 pg/mL. Only two patients with evaluable re-
sponses had HGF levels ≥600 pg/mL. The median HGF level
in four patients with SD was 337 pg/mL (150–999), which
was only slightly lower than in patients who had PD, 419 pg/
mL (236–1447). There was no correlation between the basal
level of HGF and response among patients who achieved SD
versus those who did not (P = 0.783). Four of the five patients
not evaluable for response, and one patient who had PD after
3 cycles, had high HGF levels, with a median value of
2891 pg/mL (577.7–11,976; Fig. 2a, c). Of the patients who
had highHGF levels, only 20% (1 patient) stayed on treatment
for >2 cycles, while 73% with low levels stayed on treatment
for >2 cycles (Fig. 2a, b). Although there were no significant
differences in the HGF levels between SD and PD groups at
baseline, HGF levels decreased in three of four patients that
achieved SD, while of the six evaluable patients with PD,
HGF increased in four during therapy (Fig. 2a, b).
Gene expression profiling
Of the 12 CD138+ samples available, 9 provided RNA suit-
able for GEP. The obtained data were analyzed by gene set
enrichment analysis (GSEA) run between the high (n = 2)
versus low HGF (n = 7) groups. Because the sample number
was low in the high HGF group, a t test could not be conduct-
ed, and the two high HGF samples available were from
inevaluable patients. To identify a gene set that was enriched
in the high versus low HGF group, we selected gene sets with
a false discovery rate of <0.05. This analysis revealed that
Table 1 Baseline demographic and clinical characteristics of patients
enrolled in this phase II study of tivantinib (N = 16)
Characteristic No. %
Age (median, range) 66.3 (49–76)
≤65 years 6 37.5














Prior autologous stem cell transplantation
Yes 10 62.5
No 6 37.5
Prior lines of therapy (median, range) 2.5 (2–3)













interferon response genes were associated with the high HGF
phenotype (Supplementary Table 1). One differentially
expressed gene was Interferon regulatory factor (IRF) 4,
which is required for production of immunoglobulin-
secreting plasma cells [17]. In our GEP analysis, samples from
patients who had high HGF had higher average IRF4 expres-
sion compared to samples from patients with low HGF
(Supplementary Fig. 1). Moreover, two patients who had high
HGF levels were on the trial for <2 cycles due to PD and were
not evaluable for response.
Table 2 Hematologic and
nonhematologic toxicities in
patients treated with tivantinib
(N = 16)
Toxicity grade 1 2 3 4
No. % No. % No. % No. %
Hematological toxicity type





Pain 13 81.3 2 12.5
Syncope 2 12.5
Infection 2 12.5
Fatigue 15 93.8 1 6.3
Cougha 7 43.8 1 6.3
Pulmonary embolus(i) 1 6.3
Sinus bradycardia 3 18.8
Allergic rhinitisa 2 12.5
Insomniaa 2 12.5
Metabolism/NDa 2 12.5
Musculoskeletal/connective TD 2 12.5
Peripheral sensory neuropathya 10 62.5
Myalgia 9 56.3
Skin/subcutaneous TDa 8 50.0
Diarrhea 6 37.5
Constipationa 5 31.3
Renal/urinary disordera 5 31.3
Respiratory disorder 5 31.3
Maculopapular rash 5 31.3
Memory impairment 5 31.3
Blurred visiona 5 31.3
Dry eyea 4 25.0




Gastrointestinal disordera 2 12.5
Nausea 2 12.5
Watery eyes 2 12.5
Alopecia 2 12.5
Dry skina 2 12.5
Anxietya 2 12.5
ND nutritional deficiency, TD tissue disorder
a Unrelated to the treatment
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Discussion
The c-MET receptor tyrosine kinase proto-oncogene regulates
cell growth, survival, and migration, and c-MET signaling
after engagement of its ligand, HGF, is a contributor to the
pathogenesis of myeloma. HGF and c-MET expression at the
mRNA and protein levels has been found in most myeloma
cell lines and primary samples [18, 19]. Studies correlating
HGF levels with clinical parameters showed that HGF was
elevated at diagnosis in the serum and marrows of patients
[20–22] and that HGF levels were elevated in patients with
more aggressive disease [21–23], correlating with an inferior
prognosis [22, 24, 25]. Conversely, declining HGF levels are
seen in patients responding to anti-myeloma therapies
[26–28], and patients with low HGF levels were more likely
to achieve high-quality responses [26, 29]. Furthermore, re-
duction ofMET using shRNAs [30] or a ribozyme [31] result-
ed in growth inhibition and apoptosis of myeloma cell lines.
Collectively, these findings provided a rationale for studying
tivantinib, a small-molecule, non-ATP-competitive c-MET in-
hibitor which binds to and stabilizes inactive c-MET [32].
Tivantinib was well-tolerated in our patients, and the tox-
icities were mild and manageable, with a low rate of grade 3–4
events consistent with the known AE profile of this agent.
Fig. 1 Monoclonal protein
evolution prior to and during
tivantinib therapy for stable
disease patients. Only patients 2,
5, and 12, who experienced
longer durations of therapy on
protocol, are depicted
Table 3 The most common
reported MD Anderson Symptom
Inventory (MDASI) symptoms
and their severity during
tivantinib treatment
Trial MDASI Symptom Score, median (range)
Patient Pain Fatigue Numbness Muscle weakness Limited activity
ARQ 1 0 (0) 2 (0–2) 0 (0) 0 (0–2) 0 (0)
ARQ 2a 2 (0–2) 3 (0–7) 1 (1–3) 0 (0–2) 0 (0–1)
ARQ 3 6 (2–6) 5 (3–7) 7 (4–8) 5 (3–8) 6 (4–8)
ARQ 4a 0 (0) 0 (0) 0 (0–7) 0 (0) 0 (0)
ARQ 5a 4.5 (1–6) 3 (1–6) 0 (0) 0 (0) 0 (0–1)
ARQ 6 6 (5–7) 8 (6–9) 7 (6–8) 4 (4–6) 5 (4–7)
ARQ 7 0 (0) 0 (0) 2 (0–2) 0 (0) 0 (0)
ARQ 9 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
ARQ 12a 1 (0–1) 0 (0) 0 (0) 0 (0) 0 (0)
ARQ 13 1 (1–2) 1 (1–2) 0 (0) 0 (0–1) 1 (1)
ARQ 14 0 (0) 2 (1–2) 0 (0) 0 (0) 0.5 (0–2)
a Denotes four patients who had stable disease response
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This conclusion is supported by data collected using the
MDASI, which did not indicate that therapy was poorly tol-
erated, with only few patients indicating >10 symptoms af-
fecting their activity and the enjoyment of life negatively on
treatment. Quality of life measurements using the EORTC
QLQ-C30 and QLQ-MY20 were similarly indicative of rela-
tively good tolerance, with overall health and quality of life
judged as great by the majority.
Stable disease was seen in 4/11 evaluable patients as the
best response, yielding a disease control rate of 36%, but no
patients had a PR or better. A recent study by Lendvai et al.
[33] evaluated the activity of cabozantinib, a multi-targeted
tyrosine kinase inhibitor that suppresses MET activation.
Among 12 patients, one minimal response was seen, eight
patients had SD, and two suffered PD. One explanation for
this lack of activity could be that HGF levels, while variable
among our patients, were mostly in the low range and were
not reported by Lendvai and colleagues. Of note, clinical stan-
dards for HGF levels have not been established, and we there-
fore based our cutoff for high vs. low based on data from the
literature and from the data we obtained by examining the
HGF levels in the two healthy donors (Fig. 2c). Data from
Verstovsek et al. determined the HGF level in normal plasma
samples to be 164–522.3 pg/mL, while the data from Sakon
Table 4 The most commonly reported EORTC QLQ-C30 (multiple myeloma) symptoms and their severity during tivantinib treatment
Trial patient EORTC QLQ-C30 Multiple Myeloma Symptom Score
Qualitative measures (Not at all = 1a; A little = 2a; Quite a bit = 3a; Very much = 4a), median
(range)




Long walk problem Pain/aches Weakness Tiredness Overall health Overall quality of life
ARQ 1 1 (1) 1 (1–2) 1 (1) 1 (1) 1 (1–2) 7 (6–7) 7 (6–7)
ARQ 2b 2 (1–2) 2 (1–3) 1 (1) 2 (1–3) 1 (1–3) 4 (4–6) 5 (3–6)
ARQ 3 3 (2–4) 2 (1–3) 3 (2–3) 3 (2–3) 3 (2–3) 4 (3–5) 4 (2–5)
ARQ 4b 1 (1–2) 1 (1) 1 (1) 1 (1) 1 (1–3) 7 (6–7) 7 (6–7)
ARQ 5b 1 (1) 1 (1–2) 1 (1–3) 1 (1) 2 (1–2) 6 (4–6) 6 (5–7)
ARQ 6 3 (3) 3 (3) 2 (2–3) 3 (3–4) 3 (3–4) 5 (2–6) 6 (3–6)
ARQ 7 1 (1) 1 (1) 1 (1) 1 (1) 1 (1) 7 (7) 7 (7)
ARQ 9 1 (1–4) 1 (1) 1 (1) 1 (1) 1 (1) 7 (7) 7 (7)
ARQ 12b 1 (1–2) 1 (1) 1 (1–2) 1 (1) 1 (1–2) 7 (2–7) 7 (1–7)
ARQ 13 3 (3) 3 (3) 2 (2) 1 (1) 2 (2) 6 (6) 7 (7)
ARQ 14 1 (1) 1 (1) 1 (1) 1 (1) 2 (1–2) 7 (6–7) 7 (7)
EORTC QLQ-C30 European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30
aQualitative measures assigned numbers to allow quantification of symptoms


































































































































Fig. 2 Plasma HGF levels in evaluable patients. Plasma HGF levels
(pg/mL) were measured by ELISA in patients with a progressive
disease, b stable disease, and c patients who were not evaluable for
response. The number of cycles of tivantinib received, and whether the
patient had prior autologous stem cell transplant (Auto SCT), is indicated.
High HGF samples are labeled with a black bar, and low HGF samples
are labeled with a gray bar. HD indicates healthy donors used as controls
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et al. determined the HGF level in normal plasma samples to
be 90 pg/mL. Our analysis of HGF levels in two healthy
donors yielded levels of 60 and 1400 pg/mL. Therefore, we
conservatively set the high HGF level to be any value
>2000 pg/mL, and low to be ≤2000 pg/mL [34, 35]. If we
accept these definitions, this suggests the possibility that the
myeloma cells from our patients were not especially depen-
dent on HGF/c-MET signaling and that selected patients with
high HGF levels could have fared better. While speculative,
this hypothesis is supported by the observation that HGF
levels generally tended to decrease for patients with SD com-
pared to those who progressed. Furthermore, two patients who
had high HGF levels and high IRF4 expression were on the
trial for only 1 cycle each due to PD, suggesting a worse
disease biology. However, median HGF levels between the
two groups did not differ statistically, and the small sample
size limits the ability to make strong conclusions.
After completion of our patient enrollment, several groups
published data questioning the role of tivantinib as a specific
MET inhibitor. Basilico et al. noted that tivantinib exerted
cytotoxic activity that was not influenced by c-MET gene
copy number [36]. Katayama et al. found that tivantinib
showed similar potency against c-MET-addicted and
nonaddicted cells [37] and that tivantinib induced a G2/M
arrest, while other c-MET inhibitors induced G0/G1 arrest.
Finally, in silico studies identified microtubules as potential
tivantinib targets, and microtubule disruption was noted in
treated cell lines. This led Katayama and colleagues to con-
clude that tivantinib inhibited microtubule polymerization in
addition to inhibiting c-MET. Perhaps because the growth
fraction of human myeloma cells is typically low,
microtubule-targeting agents have not shown strong activity
in this disease. If tivantinib does indeed work in part as a
microtubule inhibitor, this could also explain its lack of effi-
cacy in our patients.
Given the questions surrounding tivantinib, this study and
the trial of Lendvai et al. with cabozantinib have not eliminat-
ed the possibility that targeting c-MET may be a useful treat-
ment strategy for some relapsed and/or refractory myeloma
patients. It would be rational to consider using more specific
inhibitors in patients with high HGF levels or, better yet, with
c-MET pathway activation judged by GEP or phospho-c-
MET levels. Further, combination strategies with other anti-
myeloma therapeutics, including proteasome inhibitors, may
be an attractive option, since c-MET activation may be asso-
ciated with clinical drug resistance [38].
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